McKesson Corporation $MCK Shares Acquired by Rakuten Investment Management Inc.

Rakuten Investment Management Inc. boosted its stake in shares of McKesson Corporation (NYSE:MCK) by 5.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 20,958 shares of the company’s stock after purchasing an additional 1,166 shares during the period. Rakuten Investment Management Inc.’s holdings in McKesson were worth $18,125,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in MCK. AIA Group Ltd boosted its holdings in shares of McKesson by 10.5% in the third quarter. AIA Group Ltd now owns 1,449 shares of the company’s stock worth $1,237,000 after buying an additional 138 shares during the last quarter. Third View Private Wealth LLC raised its holdings in McKesson by 25.1% in the 3rd quarter. Third View Private Wealth LLC now owns 419 shares of the company’s stock worth $358,000 after purchasing an additional 84 shares during the period. Provenance Wealth Advisors LLC increased its position in McKesson by 294.1% in the third quarter. Provenance Wealth Advisors LLC now owns 2,321 shares of the company’s stock worth $1,982,000 after buying an additional 1,732 shares in the last quarter. TrinityBridge Ltd increased its position in McKesson by 43.3% in the third quarter. TrinityBridge Ltd now owns 50,445 shares of the company’s stock worth $43,115,000 after buying an additional 15,240 shares in the last quarter. Finally, Associated Banc Corp purchased a new position in shares of McKesson during the 3rd quarter valued at about $202,000. 85.07% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting McKesson

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: McKesson earned $11.68 per share, above the roughly $10.72 consensus, and revenue was $110.96 billion versus estimates of $109.90 billion. EPS rose from $9.86 a year earlier, while revenue increased 7.5% year over year—evidence of stronger-than-expected quarterly performance. McKesson quarterly earnings results
• Positive Sentiment: Shares also benefited from positive sentiment around peer Cencora’s earnings, according to coverage of McKesson’s move. McKesson gains after rival Cencora files earnings
• Neutral Sentiment: The board affirmed McKesson’s regular quarterly dividend of $0.94 per share, payable January 4, 2027. The reaffirmation supports continuity in shareholder returns but does not signal a dividend increase. Why McKesson is back in the spotlight
• Neutral Sentiment: Before the report, analysts flagged branded-drug pricing pressure as a potential counterweight to prescription-volume, specialty-distribution and oncology growth. The provided results coverage does not clarify how those pressures may affect future performance. Will pharma and specialty demand offset pricing headwinds?

Insiders Place Their Bets

In related news, EVP Francisco Fraga sold 800 shares of McKesson stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $995.80, for a total value of $796,640.00. Following the completion of the transaction, the executive vice president owned 5,423 shares in the company, valued at approximately $5,400,223.40. This trade represents a 12.86% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Napoleon B. Rutledge, Jr. sold 111 shares of the company’s stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $891.45, for a total value of $98,950.95. Following the sale, the chief accounting officer owned 521 shares in the company, valued at approximately $464,445.45. This trade represents a 17.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,212 shares of company stock valued at $1,164,182 in the last quarter. 0.06% of the stock is currently owned by insiders.

McKesson Stock Performance

MCK stock opened at $1,069.31 on Thursday. The company’s fifty day moving average price is $931.17 and its 200-day moving average price is $865.74. McKesson Corporation has a one year low of $723.68 and a one year high of $1,073.95. The company has a market capitalization of $124.67 billion, a PE ratio of 28.61, a price-to-earnings-growth ratio of 1.99 and a beta of 0.27.

McKesson (NYSE:MCK) last announced its quarterly earnings results on Wednesday, November 4th. The company reported $11.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.72 by $0.96. The company had revenue of $110.96 billion for the quarter, compared to the consensus estimate of $109.90 billion. McKesson had a net margin of 1.12% and a negative return on equity of 253.21%. McKesson’s revenue for the quarter was up 7.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $9.86 EPS. On average, research analysts predict that McKesson Corporation will post 44.71 EPS for the current fiscal year.

McKesson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, January 4th. Shareholders of record on Tuesday, December 1st will be issued a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.4%. The ex-dividend date is Tuesday, December 1st. McKesson’s dividend payout ratio (DPR) is currently 10.06%.

Analysts Set New Price Targets

A number of equities research analysts have commented on the stock. UBS Group raised their target price on shares of McKesson from $1,080.00 to $1,200.00 and gave the stock a “buy” rating in a research note on Friday, October 16th. Wells Fargo & Company upped their price target on shares of McKesson from $812.00 to $933.00 and gave the stock an “equal weight” rating in a research report on Tuesday, August 11th. Leerink Partners increased their price objective on shares of McKesson from $1,030.00 to $1,070.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 7th. Evercore restated an “outperform” rating and set a $950.00 price objective (down from $1,000.00) on shares of McKesson in a research report on Thursday, August 6th. Finally, Wall Street Zen upgraded shares of McKesson from a “hold” rating to a “buy” rating in a research report on Saturday, October 17th. Fifteen research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $997.12.

McKesson Company Profile

McKesson Corporation is a healthcare services and information technology company that distributes pharmaceuticals and medical products to pharmacies, hospitals, health systems, physicians and other healthcare providers. The company also provides technology, data and business solutions designed to support prescription management, pharmacy operations and patient care.

McKesson’s principal activities include pharmaceutical distribution, medical-surgical supply distribution, specialty pharmaceutical services and oncology care support.